ClinicalTrials.gg
TerminatedNCT05155020Updated Oct 12, 2022

A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma

A Phase 2 interventional study of AK120 and AK120 in Asthma, sponsored by Akeso. Terminated at 19 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Why this study was terminated
The clinical development strategy has been changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
182nd of 182
1 · median 203
Started
2022
with 20 others
Phase 2
39 of 251
19 open now
Registered
113th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 182nd largest by enrollment of the 182 interventional ones that give a count, is one of 21 that started in 2022, is one of 39 in phase 2, and was the 113th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study. The purpose of this study is to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma and not adequately controlled with current stable medium-to-high-dose inhaled glucocorticoids plus up to two additional controllers.Subjects will be randomized to receive AK120 or placebo subcutaneous injection.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • AK120
  • Efficacy
  • Safety
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female subjects aged ≥18 years old and ≤75 years old;
  2. Asthma was diagnosed ≥ 12 months before screening, current stable treatment with medium-to-high-dose inhaled plus up to two additional controllers ≥ 3 months;
  3. Blood eosinophil≥ 200 cells per microliter within 6 months before screening;
  4. During the screening, 40% of the predicted normal value \< pre-bronchodilator \< 80% of the predicted normal value, within 12 months before randomization, reversible airflow restriction was recorded;
  5. Asthma was inadequately controlled;
  6. For women with , they are not pregnant or lactating, and the subjects and their partners voluntarily take effective measures judged by the investigators during the treatment and at least 3 months after last dose.

Key Exclusion Criteria:

  1. Subjects with lung diseases other than asthma, which may affect the subject's health or end point evaluation of the study;
  2. Subjects had severe exacerbation events or systemic glucocorticoids usage within 1 month before randomization;
  3. Respiratory tract infection and any serious infection within 1 month before randomization;
  4. Subjects with parasitic infection, active tuberculosis infection, , , (HIV) or syphilis positive confirmation test;
  5. Known or suspected history of ;
  6. History of malignant tumors;
  7. A history of smoking: those who had quit smoking for ≤ 6 months before screening, or smoking history > 10 pack per year;
  8. Previous treatment with interleukin-4 (IL-4) or interleukin-13 (IL-13) inhibitors, and inadequate of other biologic therapy;
  9. Allergen immunotherapy within 3 months before randomization;
  10. Progressive or uncontrolled other diseases or any other conditions or abnormal laboratory tests for which the investigator assess that the subjects are not suitable to enrol in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    AK120 regimen 1

    Biological: AK120

  • Experimental
    AK120 regimen 2

    Biological: AK120

  • Experimental
    AK120 regimen 3

    Biological: AK120

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalAK120

    AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.

  • BiologicalAK120

    AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.

  • BiologicalAK120

    AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.

  • BiologicalPlacebo

    Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.

06

What researchers measure

Primary outcomes

  1. Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) from baseline at week 12.

    Time frame: At week 12

Secondary outcomes

  1. Annualized rate of severe exacerbation events within 24 weeks.

    Time frame: Baseline to Week24

  2. Annualized rate of severe exacerbation events within 32 weeks.

    Time frame: Baseline to Week32

  3. Change in pre-bronchodilator FEV1 from baseline to week 32.

    Time frame: Baseline to Week32

  4. Percentage change in pre-bronchodilator FEV1 from baseline to week 32.

    Time frame: Baseline to Week32

  5. Change in post-bronchodilator FEV1 from baseline to week 32.

    Time frame: Baseline to Week32

  6. Change in fractional exhaled nitric oxide (FeNO) from baseline to week 32.

    Time frame: Baseline to Week32

  7. Changes in asthma control questionnaire (ACQ-5) scores from baseline to week 32.

    Time frame: Baseline to Week32

  8. Change in standardized version of the asthma quality of life (AQLQ-s) scores from baseline at week 12 and 24.

    Time frame: at week 12,week 24

  9. Safety assessment: treatment-emergent adverse events (TEAE), serious adverse events (SAE) .

    Time frame: Baseline to Week32

  10. Pharmacokinetics (PK): AK120 concentration at different time points.

    Time frame: Baseline to Week32

  11. Immunogenicity assessment: number and percentage of subjects with detectable anti-AK120 antibody (ADA).

    Time frame: Baseline to Week32

07

Study locations

19 sites
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui, China
  • Beijing Jingmei General Hospital
    Beijing, Beijing, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • The Third Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Cangzhou People's Hospital
    Cangzhou, Hebei, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Luoyang Central Hospital
    Luoyang, Henan, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
  • Baogang Hospital, Inner Mongolia, China
    Baotou, Inner Mongolia, China
  • Inner Mongolia People's Hospital
    Hohhot, Inner Mongolia, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu, China
  • Jiangxi Provincial Prople's Hospita
    Nanchang, Jiangxi, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, Jiangxi, China
  • Jilin Province People's Hospital
    Changchun, Jilin, China
  • Shanghai General Hospital
    Shanghai, Shanghai, China
  • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • Zhongshan Hospital Fudan University
    Shanghai, Shanghai, China
  • First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine,
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Aug 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2021
First posted
Dec 13, 2021
StartActual
Feb 11, 2022
Primary completionActual
Aug 5, 2022
CompletionActual
Aug 5, 2022
Last update
Oct 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05155020
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Dec 13, 2021
Start date
Feb 11, 2022
Primary completion
Aug 5, 2022
Completion
Aug 5, 2022
Last update
Oct 12, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK120

Start the discussion